Capsule Summary
Conference Capsule - (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - August 1, 2017 Category: Infectious Diseases Source Type: research
Key Studies Influencing My Practice Following IAS 2017
Slideset - In this downloadable slideset from a recent live Webinar, expert faculty members Anton L. Pozniak, MD, FRCP, and Kathleen E. Squires, MD, highlight key studies from IAS 2017 that are anticipated to affect clinical practice. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
ZEST: Greater Improvements in Bone Mineral Density With Zoledronic Acid vs Switch From TDF in HIV-Infected Osteopenic Men on Stable TDF-Containing ART Over 2 Years
Conference Capsule - eGFR was significantly lower with zoledronic acid vs TDF switch, despite improvements in bone mineral density. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
ANRS CO4 French Hospital Database on HIV Case-Control Study Finds No Excess Risk of Fracture Following Exposure to Tenofovir DF or PIs
Conference Capsule - Lower risk of fracture was associated with cumulative efavirenz exposure, although no causal link found. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
Key Studies Influencing My Practice Following IAS 2017
Slideset - In this downloadable slideset from a recent live Webinar, expert faculty members Anton L. Pozniak, MD, FRCP, and Kathleen E. Squires, MD, highlight key studies from IAS 2017 that are anticipated to affect clinical practice. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
ZEST: Greater Improvements in Bone Mineral Density With Zoledronic Acid vs Switch From TDF in HIV-Infected Osteopenic Men on Stable TDF-Containing ART Over 2 Years
Conference Capsule - eGFR was significantly lower with zoledronic acid vs TDF switch, despite improvements in bone mineral density. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
ANRS CO4 French Hospital Database Cohort Case-Control Study Finds No Excess Risk of Fracture Following Exposure to Tenofovir DF or PIs
Conference Capsule - Lower risk of fracture was associated with cumulative efavirenz exposure, although no causal link found. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 28, 2017 Category: Infectious Diseases Source Type: research
GS-1490: Single-Pill Coformulation of Bictegravir/Emtricitabine/Tenofovir Alafenamide Noninferior to Dolutegravir Plus Emtricitabine/Tenofovir Alafenamide at Week 48 in Treatment-Naive Patients
Conference Capsule - HIV-1 RNA (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 27, 2017 Category: Infectious Diseases Source Type: research
NEAT 022: Switch From Boosted PI –Based ART to Dolutegravir-Based ART Maintains Virologic Suppression, Improves Lipid Profile in Virologically Suppressed Patients With High CVD Risk
Conference Capsule - Efficacy of switch to INSTI-based regimen noninferior to continued PI treatment at Week 48 in older HIV-infected population with multiple risk factors for cardiovascular disease. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 27, 2017 Category: Infectious Diseases Source Type: research
Study 1490: Single-Pill Coformulation of Bictegravir/Emtricitabine/Tenofovir Alafenamide Noninferior to Dolutegravir Plus Emtricitabine/Tenofovir Alafenamide at Week 48 in Treatment-Naive Patients
Conference Capsule - HIV-1 RNA (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 27, 2017 Category: Infectious Diseases Source Type: research
DRIVE-AHEAD: Once-Daily Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Noninferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Patients
Conference Capsule - In addition to demonstrating comparable efficacy, DOR/3TC/TDF produced significantly fewer neuropsychiatric AEs and had a more favorable impact on fasting lipid levels in comparison with EFV/FTC/TDF. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 27, 2017 Category: Infectious Diseases Source Type: research
HPTN 077: Long-Acting Injectable Cabotegravir Demonstrates Acceptable Safety and Adequate Drug Exposure in HIV-Uninfected Individuals
Conference Capsule - Cabotegravir demonstrates good tolerability in preliminary study of use of this strategy for potential PrEP candidate. (Source: Clinical Care Options HIV)
Source: Clinical Care Options HIV - July 27, 2017 Category: Infectious Diseases Source Type: research
